Recently, the General Office of the CPC Central Committee and the General Office of the State Council issued the "Opinions on Further Improving the Medical and Health Service System," clearly requiring strengthening the development and capacity building of clinical medicine, public health, and medical device research and development systems, and accelerating the filling of gaps in high-end medical equipment. In the post-pandemic era, the market's demand for innovative iterations of medical products has also been strong, bringing about historic development opportunities for the innovative medical device industry.
"Integrate Medical Innovation, Create a Healthy Future", co-hosted by Binlingxing Venture Capital and Artery Network2023The 7th Future Medicine Conference100The Strong Conference Sub-forum - Cross-disciplinary Technology Clinical Application Forum of Medical Devices will be held on2023year5month5The conference was successfully held in Shanghai on the 1st. The forum aims to strengthen the linkage of industry, academia, research, and medicine, promote interdisciplinary exchanges, integrate perspectives from different angles such as clinical practice, technology, and market, empower innovative thinking in industrial integration, jointly explore the possibility of technological innovation breakthroughs that transcend existing scientific and technical boundaries in medical devices, and their potential value in addressing major clinical issues.
On the forum, several industry experts, clinicians, and nearly20Medical device entrepreneurs discussed in depth the development and application trends of technological innovation in the medical device industry. The keynote speeches at the conference explored how to "promote global innovation into clinical practice in China through multi-party cooperation," "innovation practices based on clinical needs," and investigated "the path of innovative device development in China." Subsequently, the participating guests engaged in three roundtable discussions around hot topics such as innovative technology platforms for major diseases, clinical applications of interdisciplinary technological innovation, and intelligent and automated trends, engaging in in-depth views exchange and technical communication.
Swipe left and right to view more photos from the event
Sun Xiaolu, a partner at Binjiang Venture Capital, attended the forum and delivered an opening speech; Shen Li, Chief Physician of the Department of Cardiology at Zhongshan Hospital Affiliated to Fudan University and Director of the Office of the National Clinical Research Center for Radiation and Therapy, attended the event and delivered a keynote speech titled 'Innovative Practices Based on Clinical Needs'. Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, attended the event and delivered a speech on “ Delivered a keynote speech on "Exploration of the Development Path of Innovative Medical Devices in China"; Binjiang Star Venture Capital Partners Li Zhe, Kangfeng BiologyCEOZhu Jun and Wang Zhengbin, Managing Director of Binlinxing Venture Capital, attended the meeting and presided over roundtable forums respectively; He Yuping, Founder of Dunbo Medical, Zhang Ruian, Deputy General Manager of Jianshi Technology,Lifeshield MedicalChen Zulin, General Manager of Life Shield Medical China; Li Yunxiang, Founder of NanoViz; Wang Yongsheng, General Manager of Weiqiang Medical; Le Bin, Founder of Yichao Medical; Chen Shixing, Co-founder of ChaoGuang Micro Medical; Xu Tianrui, Founder of Lingchuang Medical Valley; Wang Zhengbin, Director of Puluo Medical; Ruidi BiotechnologyCFOXu Yingrui, Founder of Ruining Biotechnology, Pan Zhen, Founder of Dawan BiotechnologyCEOCo-founder and co-founder-in-chief Chen Liang, DaRong TechnologyCEOZhou Yu, HanzandiCMOHe Dan, Zhu Jianjun, the AI R&D Director at Hengle Technology, and Wang Zhen, the founder of Vision Medical, along with other founders of medical device companies invested by Bilingxing Venture Capital, attended the meeting and participated in roundtable discussions; the forum was chaired by Sun Shanshan, the Executive Director of Bilingxing Venture Capital.
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
Mao Hua said, China's medical device market size ranks second globally, but per capita consumption is far lower than that of the United States, leaving significant room for development. He pointed out that Medical devices belong to the high-end manufacturing industry and require innovative development along with manufacturing collaboration. Manufacturing is one of China's strongest fields and already possesses considerable competitive advantages. In the future, after catching up in technological innovation, China's medical device industry will shift from the past imitation model to independent innovation and further towards globalization.
Looking at the sub-sectors of medical devices, cardiovascular intervention, robotics, and imaging have become the most favored areas for capital investment, consistently ranking among the top in terms of investment and financing transactions for three consecutive years.Top 3The field of cardiovascular intervention is undergoing innovation in multiple dimensions such as procedures, materials, and technology. The era of robotics is subverting various traditional surgeries and presenting trends towards informatization, intelligence, minimally invasive techniques, etc. In the field of medical imaging, big data, intelligenceAIThe application trend of intraoperative image fusion technology is significant.
Mao Hua's detailed data analysis points out that strong policy support, active capital assistance, the return of outstanding talents, and diverse innovation models are the fundamental driving forces behind the rapid development of innovative medical devices in China. In the primary market, early investment in platforms, incubation, and niche areas is favored. In the secondary market, companies choose to go public with more diversification, valuing commercial capabilities and their own self-sustaining abilities. This indicates that investment and financing in innovative medical devices are returning to rationality. Focusing on clinical pain points, capturing the world's most cutting-edge technologies, and combining precision diagnosis and treatment with digitization will be important directions for future technological innovation. The characteristics of medical devices determine their diverse sub-sectors and tracks, requiring investment to value the integrity of the industrial chain more, layout core components and key raw materials, and place more emphasis on R&D, cooperation, and business model diversification.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
